Novo hunts for ‘maximum potential’ from obesity drug CagriSema
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target
Related reading
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
New Novo Nordisk drug could beat market leaders for weight loss, early results…
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose